Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 29, Issue 2, 2006, Pages 109-115

  Lockhart, Albert Craig ^a,c,e   Cropp, Gillian F ^b   Berlin, Jordan D ^a,c   Donnelly, Edwin ^a,c   Schumaker, Robert D ^a,c   Schaaf, Larry J ^d   Hande, Kenneth R ^a,c   Fleischer, Arthur C ^a,c   Hannah, Alison L ^b   Rothenberg, Mace L ^a,c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b Surgen Inc   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

^d PFIZER INC   (United States)

^e Division of Hematology   (United States)

Author keywords

5 fluorouracil; Angiogenesis; Irinotecan; Phase I clinical trial; Semaxinib; SU5416; Tyrosine kinase inhibitor

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; VASCULOTROPIN RECEPTOR 2; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD SAMPLING; BLOOD TOXICITY; BOLUS INJECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTRAST ENHANCEMENT; DEHYDRATION; DIARRHEA; DOPPLER ECHOGRAPHY; DRUG CLEARANCE; DRUG DETERMINATION; DRUG HALF LIFE; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; HUMAN; HYPERTENSION; INFECTION; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; NAUSEA; NEUTROPENIA; PAIN; PERFUSION; PHASE 1 CLINICAL TRIAL; PILOT STUDY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SIDE EFFECT; THROMBOSIS; TREATMENT RESPONSE; URINE RETENTION; VEIN THROMBOSIS; VOMITING; WEIGHT REDUCTION; COLORECTAL TUMOR; DRUG ADMINISTRATION; DRUG ANTAGONISM; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INDOLES; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PYRROLES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 33645778849     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000199882.53545.ac     Document Type: Article

References (42)

1. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990;82:4-6.
2. Engels K, Fox SB, Whitehouse RM, et al. Distinct angiogenic patterns are associated with high-grade in situ ductal carcinomas of the breast. J Pathol. 1997;181:207-212.
3. Gasparini G, Weidner N, Maluta S, et al. Intratumoral microvessel density and p53 protein: correlation with metastasis in head-and-neck squamous-cell carcinoma. Int J Cancer. 1993;55:739-744.
4. Hayes DF. Angiogenesis and breast cancer. Hematol Oncol Clin North Am. 1994;8:51-71.
5. Seo Y, Baba H, Fukuda T, et al. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer. 2000;88:2239-2245.
6. Shih CH, Ozawa S, Ando N, et al. Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. Clin Cancer Res. 2000;6:1161-1168.
7. Takanami I, Tanaka F, Hashizume T, et al. Vascular endothelial growth factor and its receptor correlate with angiogenesis and survival in pulmonary adenocarcinoma. Anticancer Res. 1997;17:2811-2814.
8. Weidner N, Carroll PR, Flax J, et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993;143:401-409.
9. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 2002;20:4368-4380.
10. Dvorak HF, Brown LF, Detmar M, et al. Vascular permeability factor/ vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995;146:1029-1039.
11. Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res. 1993;53:4727-4735.
12. Cascinu S, Staccioli MP, Gasparini G, et al. Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res. 2000;6:2803-2807.
13. Ellis LM, Takahashi Y, Liu W, et al. Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. Oncologist. 2000;5:11-15.
14. Ishigami SI, Arii S, Furutani M, et al. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer. 1998;78:1379-1384.
15. Takahashi Y, Kitadai Y, Bucana CD, et al. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995;55:3964-3968.
16. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [see comment]. N Engl J Med. 2004;350:2335-2342.
17. Levitzki A. Protein tyrosine kinase inhibitors as novel therapeutic agents. Pharmacol Ther. 1999;82:231-239.
18. Hubbard SR. Protein tyrosine kinases: autoregulation and small-molecule inhibition. Curr Opin Struct Biol. 2002;12:735-741.
19. Mendel DB, Laird AD, Smolich BD, et al. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des. 2000;15:29-41.
20. Fong TA, Shawver LK, Sun L, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 1999;59:99-106.
21. Shaheen RM, Davis DW, Liu W, et al. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res. 1999;59:5412-5416.
22. Cropp G, Rosen L, Mulay M, et al. Pharmacokinetics and pharmacodynamics of SU5416 in a phase I, dose escalating trial in patients with advanced malignancies (Abstract). Proc Am Soc Clin Oncol. 1999;18:619.
23. Rosen L, Mulay M, Mayers A, et al. Phase I dose-escalating trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies (Abstract). Proc Am Soc of Clin Oncol. 1999;18:618.
24. Rosen P, Amado R, Hecht J, et al. A phase I/II study of SU5416 in combination with 5-FU/leucovorin in patients with metastatic colorectal cancer (Abstract). Proc Am Soc of Clin Oncol. 2000;19:5D.
25. Miller LL, Elfring GL, Hannah AL, et al. Efficacy results of a phase I/II study of SU5416 (S)/5-fluorouracil (F)/leucovorin (L) relative to results in random subsets of similar patients (pts) from a phase III study of irinotecan (C)/F/L or F/L alone in the therapy of previously untreated metastatic colorectal cancer (MCRC) (Abstract). Proc Am Soc Clin Oncol. 2001;20:571.
26. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group (see comment). N Engl J Med. 2000;343:905-914.
27. Sparreboom A, de Bruijn P, de Jonge MJ, et al. Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces. J Chromatogr B Biomed Sci Appl. 1998;712:225-235.
28. Stopeck A, Sheldon M, Vahedian M, et al. Results of a phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Clin Cancer Res. 2002;8:2798-2805.
29. Forsberg F, Ro RJ, Potoczek M, et al. Assessment of angiogenesis: implications for ultrasound imaging. Ultrasonics. 2004;42:325-330.
30. Muniz CJ, Fleischer AC, Donnelly EF, et al. Three-dimensional color Doppler sonography and uterine artery arteriography of fibroids: assessment of changes in vascularity before and after embolization. J Ultrasound Med. 2002;21:129-133.
31. Sparreboom A, de Jonge MJ, de Bruijn P, et al. Irinotecan (CPT-11) metabolism and disposition in cancer patients. Clin Cancer Res. 1998;4:2747-2754.
32. Pharmacia Corporation. SU5416 Investigator's Brochure.
33. Slatter JG, Schaaf LJ, Sams JP, et al. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following i. v. infusion of [(14)C]CPT-11 in cancer patients. Drug Metab Dispos. 2000;28:423-433.
34. Kuenen BC, Rosen L, Smit EF, et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors (see comment). J Clin Oncol. 2002;20:1657-1667.
35. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23-30.
36. Morgan B, Thomas AL, Drevs J, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies (see comment). J Clin Oncol. 2003;21:3955-3964.
37. Heymach JV, Desai J, Manola J, et al. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin Cancer Res. 2004;10:5732-5740.
38. Herbst RS, Mullani NA, Davis DW, et al. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol. 2002;20:3804-3814.
39. Andre T, Louvet C, Maindrault-Goebel F, et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer GERCOR. Eur J Cancer. 1999;35:1343-1347.
40. Ducreux M, Ychou M, Seitz JF, et al. Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. J Clin Oncol. 1999;17:2901-2908.
41. Rothenberg ML, Meropol NJ, Poplin EA, et al. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol. 2001;19:3801-3807.
42. Vanhoefer U, Harstrick A, Kohne CH, et al. Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer. J Clin Oncol. 1999;17:907-913.